Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Tag: inflammatory bowel disease
Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease
1. Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) were effective imaging modalities for the assessment of the radiologic response ...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
Adalimumab may be associated with improved outcomes in the management of pediatric Crohn’s disease
1. Maintenance therapy with adalimumab (ADA) was associated with more frequent objective improvement based on Magnetic Resonance Enterography (MRE) findings ...
#VisualAbstract: Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis
1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission ...
Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes
1. Patients who continued anti-tumor necrosis factor (TNF) after 24 weeks of pregnancy had improved inflammatory bowel disease (IBD) activity ...
ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity
1. Patients with the ACKR1 variant (CC genotype) had an elevated risk of azathioprine discontinuation attributed to hematopoietic toxicity. 2. ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis
1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies. 2. ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
